Clinical Outcomes of Extracorporeal Shock Wave Therapy (ESWT) for Joint Pain in Patients with Hypermobile Ehlers-Danlos Syndrome: A Retrospective Chart Review
Abstract
Abstract Background: Ehlers-Danlos Syndrome (EDS) is a connective tissue disorder characterized by ligamentous laxity, chronic musculoskeletal pain, joint instability, and substantial functional impairment. Chronic pain is among the most prevalent and debilitating manifestations of EDS. Current treatment options often focus on symptom management, with limited data regarding therapeutic modalities such as Extracorporeal Shock Wave Therapy (ESWT).
Objective:: To retrospectively evaluate the effects of ESWT on pain reduction and the duration of symptom relief in patients with EDS-related joint pain.
Methods:: A retrospective chart review was conducted on patients with EDS who underwent ESWT therapy for chronic joint pain. Inclusion criteria required documentation of pre- and post-treatment Visual Analog Scale (VAS) pain scores for at least three treatment sessions. Data collected included baseline demographics, treatment-specific VAS scores, and duration of symptom relief between each treatment.
Results:: A total of (N = 47) patients met inclusion criteria, consisting of (46 females, 1 male), with a mean age of 37. The average Beighton score was 6.8. Across three treatment sessions, mean pre-treatment VAS scores decreased from 6.55 to immediate post-treatment scores of 3.37, representing an average pain reduction of 48.2% with statistically significant reductions in pain (p < 0.001). Duration of symptom relief progressively improved from 1.3 days after treatment one to 3.03…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.